Oral Cancer News – Page 161

Snus spat erupts in Norway

Source: Ice News A row has erupted over snuff tobacco in Norway after a state researcher said the government should be promoting it as a way of stopping smoking. Health officials have dismissed the criticisms of Karl Erik Lund, however, saying the substance, known as snus in Norway, is highly addictive and can cause cancer. Mr Lund, of the state institute for alcohol and drug research SIRUS, told Aftenposten newspaper that Norway should start being honest with its people by telling them that snus is “much less dangerous” than smoking. Dr Maja-Lisa Løchen, a professor of preventive medicine at the Univerity of Tromsø, however, told the newspaper that she was “furious” that they had given the story “so much space”. “No research has documented that using snus is an effective way to stop smoking,” Dr Løchen told Aftenposten. “On the contrary, some smokers can wind up using both forms of tobacco.” Løchen added that users, who usually place the snus under their lips to absorb the nicotine, also risk contracting other forms of cancer. She added that the health ministry would not be recommending the product. Snus is banned in many European countries but has a long tradition of use in Norway and Sweden where it is still legal. This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2012-04-06T09:53:42-07:00April, 2012|Oral Cancer News|

Swedish Match Announces Market Expansion for General Snus

Swedish Match today announced it has expanded into 7 additional US markets with its General brand Swedish snus. General is the number #1 selling snus in the world and the flagship brand for Swedish Match. Now General will be available in convenience stores and tobacco outlets in the metropolitan areas of New York, Los Angeles, Minneapolis, Phoenix, Denver, Nashville and throughout the state of Ohio with its two new flavors in the product assortment, Nordic Mint and Classic Blend. Those flavors were launched in Chicago, Dallas and Philadelphia in mid-2011. "These particular markets were chosen because they meet a number of important criteria to maximize the success of the General brand - from local smoking restrictions to the number of adult tobacco consumers and the potential opportunity for the snus category as a whole," according to Clark Darrah, Vice President Next Generation Products. General is authentic Swedish snus crafted from a sophisticated blend of premium tobaccos using a unique GothiaTek® production process ensuring the highest measure of quality. Snus is sold in pouches that are placed inconspicuously under the user's upper lip, and is a form of smokefree and spit free tobacco that is popular among white-collar professionals throughout Scandinavia, where it first originated in the early 19th century. While the category is still young in the United States, snus has enjoyed tremendous growth of over 225% since its first introduction domestically in 2006 and is now about 6% of the smokeless tobacco category. Darrah adds, "Adult tobacco consumers are [...]

Charlotte Parker2012-04-06T09:44:02-07:00April, 2012|Oral Cancer News|

The Gardasil Problem: How The U.S. Lost Faith In A Promising Vaccine

Source: Forbes Magazine, written by Matthew Herper Neal Fowler, 50, the chief executive officer of a tiny biotech called Liquidia, was assuming a position common to road-warrior entrepreneurs: leaning his elbows on the seat-back tray in an airplane so he could gaze at the screen of his laptop. That’s when he felt the lump in his neck. Fowler, a pharmacist, figured his lymph node was swollen by a recent cold, but the oncologist seated next to him—his chairman of the board—thought they’d better keep an eye on it. The chairman was right. Over the next week the lymph node got bigger and harder. It was not sore to the touch, as happens during a cold. Fowler went to the doctor, then a specialist who knew exactly what he was seeing: a new form of throat cancer that ear, nose and throat specialists across the U.S. now say dominates their practices. Some 8,000 of these tonsil tumors turn up each year nationwide, courtesy of strain 16 of the human papilloma virus—the same sexually transmitted virus that causes cervical cancer. Usually transmitted when men perform oral sex on women, it can also spread through other forms of contact, perhaps even just kissing. His prognosis was good—80% of those with this new tumor survive. His status as a drug industry veteran and chief executive of a biotechnology company didn’t hurt, either. He went from diagnosis to having the primary tumor removed from his tonsil in just a day. His first team of doctors [...]

Charlotte Parker2012-04-05T21:25:34-07:00April, 2012|Oral Cancer News|

Declines in Smoking and Lung Cancer Mortality in the U.S.: 1975–2000

Source: Oxford Journals Although changing smoking behaviors have had a major impact on lung cancer mortality in the U.S., the numbers of lung cancer deaths averted are only a small fraction of deaths that could have been avoided had all smoking ceased following the 1964 Surgeon General’s Report. Further efforts to control tobacco use are needed to decrease the impact of the disease, according to a study published March 14 in the Journal of the National Cancer Institute. The restrictions on smoking in public places, escalations in cigarette taxes, reduced access to cigarettes, and an increased public awareness on the health issues related to smoking have all helped steadily decrease the number of smokers in the U.S. since the mid 1950’s; however, little measurable information exists in regards to the amount lung cancer deaths have diminished in association with the decline in smoking. In order to determine the effect that reduced tobacco smoking has had on lung cancer mortality in the U.S., Suresh H. Moolgavkar, M.D., Ph.D., of the Program in Biostatistics and Biomathematics at the Fred Hutchinson Cancer Research Center in Seattle, Washington and colleagues built independent models based on cohort, case-control, or registry data and adjusted to overall mortality to estimate the number of lung cancer deaths prevented between 1975–2000. The data were distinguished by sex and birth decade (1890–1970), and the prevalence of smoking and lung cancer deaths were considered based on actual tobacco control (ATC), historical changes in smoking rates, no tobacco control (NTC), predicted smoking [...]

Charlotte Parker2012-04-04T09:10:41-07:00April, 2012|Oral Cancer News|

The 795 Thousand and Ending a Century of Tobacco

Source: Oxford Journals Tonight, a grandfather will read his grandson a soothing bedtime story. Yesterday, a mother saw her son perform a brilliant violin solo. Tomorrow, a grandfather will see his granddaughter complete the first unassisted triple play in their community's t-ball league history. What do these vignettes have in common? They represent just three of the 795 851 people––the 795 thousand––whose premature deaths from lung cancer were averted in the United States through aggressive tobacco control policies and interventions between 1975 and 2000, as determined by a series of consortium-based sophisticated modeling techniques and reported by Moolgavkar et al. (1) in this issue of the Journal. Sometimes, we become inured to the sheer number of deaths caused by tobacco—for example, a predicted 1 billion tobacco-caused deaths this century, 100 million people killed by tobacco in the 20th century, 6 million deaths per year globally, 443 000 deaths per year in the United States, etc. But, despite these enormous, and even numbing, numbers, we need to remember that every one of these 1 billion, 100 million, 6 million, or 443 000, was a father, mother, brother, sister, son, or daughter who, if tobacco had not intervened, would have enjoyed, and shared, a longer, healthier, and more fulfilling life. How did this happen? How did we allow tobacco, over the past 100 years, to kill and cause disease with such abandon? And, more important, how have we begun to turn the tide against the tobacco tsunami and how can we continue to learn from [...]

Charlotte Parker2012-04-04T08:27:45-07:00April, 2012|Oral Cancer News|

Head And Neck Cancer Chemotherapy Efficacy Boosted By Human Virus

Source: MedicalNewsToday.com Preliminary data from a trial published in Clinical Cancer Research shows that a harmless human virus that occurs naturally could potentially boost the effects of two standard chemotherapy drugs in some cancer patients. Oncolytics Biotech Inc. developed a new drug, RT3D that will be marketed under the trade name of Reolysin. The drug is based on a virus, i.e. reovirus type 3 Dearing that is commonly found in the respiratory and gastrointestinal tracts of almost every adult without causing any symptoms. RT3D can grow and kill certain types of cancer cells, but it does not grow in normal cells. Earlier trials whereby patients were injected with only the virus displayed limited effectiveness, however, the team discovered that the effects of platin and taxane-based chemotherapy on tumor cells seemed to be magnified by RT3D. Dr Kevin Harrington and his team decided to start a clinical trial in which they examined intravenous RT3D in combination with chemotherapeutics carboplatin and paclitaxel in 31 patients with advanced cancers that had become unresponsive to standard treatments. They conducted an initial Phase I study in patients with a variety of advanced cancers, which demonstrated that the drug combination was safe, with generally mild side effects that were consistent with chemotherapy alone. The best responses were observed in patients with head and neck cancers, including tumors of the nasal cavity, eye, tongue, gums, lip, cheeks, voice box and esophagus. Worldwide, each year about 650,000 people are diagnosed with squamous cell cancer of the head and [...]

Charlotte Parker2012-04-03T10:50:41-07:00April, 2012|Oral Cancer News|

High purity zirconia improves speech valves

Source: www.onlinetmd.com Author: Elizabeth Engler Modic Morgan Technical Ceramics (MTC) worked with the UK-based University of Hull to develop a new valve used to restore vocal function for patients with throat cancer. The new tracheo-oesophageal fistula speech valve uses Zyranox biocompatible Yttria partially-stabilized Zirconia, specifically developed for surgical implant devices. The iterative design process for this innovative valve included a close collaboration, featuring consultation on materials, prototyping to test the design, and precision manufacturing to meet the extremely tight tolerances required. The patented new ceramic valve lasts at least eight times longer than traditionally used silicone valves, improving patient quality of life and decreasing overall healthcare costs. The device is to go to market via the spinout company Avoco Medical Ltd. Project Goals Avoco Medical was seeking to improve upon a commonly used speech restoration system for throat cancer patients, which uses a small silicone valve connecting the windpipe (trachea) and the throat (oesophagus). Air, powered by the lungs, diverts into the throat, which vibrates and results in fluent speech. Traditionally the valve is from silicone rubber, but the material exposure to hostile and non-sterile environments results in development of a biofilm on the surface. This biofilm causes valve performance to deteriorate, necessitating an uncomfortable and costly valve replacement procedure about every three months.[1] Precision Manufacturing The company was seeking a way to replace the silicone with ceramic, a more attractive material because of its stability, biocompatibility, and compliance. With its hard, impervious surface, ceramic is more resistant [...]

Oral Cancer Foundation News Team - A2012-04-03T09:21:12-07:00April, 2012|Oral Cancer News|

Researchers identify a gene that predicts recurrence in squamous cell carcinoma of the head and neck

Source: http://www.eurekalert.org/ Author: press release Squamous cell carcinoma of the head and neck—which typically arises from thin, flat cells that line moist surfaces inside the mouth, nose and throat—is the sixth most common type of cancer worldwide, and it has a relatively low five-year survival rate and a high recurrence rate. Recently, the disease has become even more prevalent among adults 40 years of age or younger. These statistics underscore the need for a greater understanding of the molecular underpinnings of this form of cancer. Toward this goal, Fox Chase Cancer Center researchers have identified a gene that predicts disease recurrence in individuals with squamous cell carcinoma of the head and neck. The new findings, which will be presented at the AACR Annual Meeting 2012 on Monday, April 2, show that patients with one common variant of a gene which encodes the cytochrome P450 (CYP1B1) protein are likely to have a longer time-to-recurrence than those with the more typical form of the gene. "This is the first study to look at the association between CYP1B1 variants and time-to-recurrence in head and neck cancer, and the findings could lead to personalized treatment strategies for patients with this type of cancer," says Fox Chase study author Ekaterina Shatalova, Ph.D., research associate in the lab of Margie L. Clapper, Ph.D., also senior investigator on the study. Shatalova, Clapper and their colleagues focused on CYP1B1 because this enzyme is known to produce carcinogens by metabolizing tobacco smoke and alcohol—substances that increase the risk of [...]

Oral Cancer Foundation News Team - A2012-04-03T09:09:51-07:00April, 2012|Oral Cancer News|

Cancer-causing chemical found in smokeless tobacco

Source: www.foxnews.com Author: staff A chemical in smokeless tobacco products has been found to cause cancer, according to a new study in animals. The chemical was a strong inducer of oral tumors, the study showed. While use of smokeless tobacco products has been strongly linked to the development of cancer, no specific chemical in the products had been identified as a strong oral-cancer causing agent until now, the researchers say. The chemical, called (S)-N'-nitrosonornicotine, or (S)-NNN, "is the only chemical in smokeless tobacco known to cause oral cancer," study researcher Silvia Balbo, a cancer researcher at the University of Minnesota, said in a statement. The finding may explain how smokeless tobacco products cause cancer, Balbo said. Balbo said the findings are an affirmation that tobacco products should be avoided. Smokeless tabacco products are already required to carry warning labels saying the products can cause mouth cancer or are not a safe alternative to cigarettes, the Food and Drug Administration says. The most common type of smokeless tobacco product is moist snuff placed in the mouth. Previous studies have suggested that a group of chemicals called nitrosamines, of which (S)-NNN is a member, cause various types of cancer in animals, but no study has looked at the carcinogenicity of (S)-NNNspecifically, the researchers say. Balbo and colleagues administered (S)-NNN to 24 rats. The rats were given (S)-NNN or tap water. The total dose was approximately equivalent to the amount of (S)-NNN to which a smokeless tobacco user would be exposed from [...]

Oral Cancer Foundation News Team - A2012-04-03T08:59:01-07:00April, 2012|Oral Cancer News|

Oral cancer breakthrough

Source: cancertreatmentmx.com Author: staff UCLA scientists have come up with a revolutionary new way of identifying oral cancer. Funded by the National Institute of Dental and Cranial Facial Research, they developed a simple saliva test that makes detecting oral cancer easy. No longer must patients wait until they find an unusual sore in their mouth or make a routine trip to their dentist:

Oral Cancer Foundation News Team - A2012-04-03T08:50:11-07:00April, 2012|Oral Cancer News|